Selected reaction monitoring (SRM) is the targeted mass spectrometry method that quantifies analytes by recording only predefined precursor-to-product reactions, called transitions, on liquid chromatography-tandem mass spectrometry (LC-MS/MS) (Lange et al. 2008). In proteomics project language, each selected reaction is a locked ion pair with dwell time and collision energy. Multiple reaction monitoring (MRM) names the same logic when many transitions run in one schedule. Parallel reaction monitoring (PRM) records a high-resolution product-ion spectrum so fragments can be chosen after acquisition (Peterson et al. 2012). The guide below integrates SRM as a monitoring method with workflow, locked parameters, limits, and project fit. It is not a food-safety or environmental methods page, not a precision-medicine brochure, and not an antibody product comparison catalog.

SRM outputs support relative change of the same peptide across frozen groups. Amount on named peptides needs stable isotope-labeled internal standard (SIS) peptides and a calibration model in the study matrix (Gerber et al. 2003). Selecting reactions buys specificity. It does not remove matrix suppression or create a clinical cutoff by itself (Bantscheff et al. 2012).

In MtoZ Biolabs targeted offerings, SRM or MRM methods are built when the transition list is closed and matrix-matched pilots support the cohort block. Service intake appears in SRM-MRM Quantitative Proteomics Services.

What Selected Reaction Monitoring Covers

Four method layers belong in the brief and stay separated.

Reaction layer defines each precursor-product pair, retention window, dwell, and collision energy. Only reactions on the inclusion list are scheduled.

Panel layer groups those reactions into a versioned protein or site map. Concurrent transitions are still SRM logic; MRM is the common name when the schedule is large.

Informatics layer covers peak integration, transition-ratio review, normalization or SIS calibration, and statistics on predefined contrasts only.

Claim layer states relative peptide change, or calibrated amount when SIS and a curve are declared. Biomarker, disease-mechanism, or drug-development language needs separate study design.

SRM monitors selected reactions. It does not invent transitions for unnamed proteins during acquisition.

SRM Versus MRM Naming, PRM, Antibody Assays, and Discovery

Route choice should separate naming from evidence needs.

SRM and MRM describe the same scheduled transition pattern on triple quadrupole LC-MS/MS. The record should lock one method name and one transition list version. Saying that SRM supports MRM usually means one schedule can hold many selected reactions, not a second orthogonal method.

PRM fits when selected reactions remain unstable after matrix-matched optimization, so product ions can be reviewed after acquisition (Gallien et al. 2012). Route choice after matrix pilot appears in Parallel Reaction Monitoring vs MRM: Which Fits?.

Antibody assays such as enzyme-linked immunosorbent assay (ELISA) measure different epitopes and need reagent availability. SRM does not require antibody generation, but it still needs proteotypic peptides, matched prep, and transition pilots. The two routes are not automatic substitutes.

Discovery label-free quantification (LFQ) or data-independent acquisition (DIA) profiles an open or semi-open list. SRM starts after candidates are named and reactions are selected. Detection-layer wording appears in Selected Reaction Monitoring Mass Spectrometry.

End-to-End Workflow for Selected Reaction Monitoring

A practical SRM spine usually runs as follows.

1. Freeze contrast, replicates, and relative versus amount claim.
2. Close the peptide panel and map each peptide to its protein or site.
3. Match extraction, digest, and load across all contrast arms.
4. Select precursor-product reactions and collision energies on matrix-matched digests.
5. Build the dwell schedule inside chromatographic peak width for the full reaction list.
6. Size biological n plus quality control (QC), blanks, and SIS if used.
7. Acquire interleaved study and QC injections when cohort size allows.
8. Integrate selected reactions; review ratios and retention drift against locked rules.
9. Test predefined contrast only; archive reaction list, method file, and software with deliverables.

Steps 1 through 3 protect the sample record. Steps 4 through 9 produce the selected-reaction quantitative record.

Figure 1. SRM comparability depends on a versioned selected-reaction list and matched pretreatment before group contrasts are tested.

Parameters That Must Be Locked in SRM Methods

Layer	Parameter that must be declared	Failure mode if ignored
Naming	SRM or MRM locked to one list version	Two names for the same schedule
Reactions	Precursor, product, dwell, collision energy	Neat-standard pairs fail in matrix
Panel	Peptide-to-protein map version	Moving targets mid cohort
Schedule	Cycle time versus peak width and reaction count	Undersampled or missed peaks
Prep	Matched extraction and digest	Peptide-pool shift as biology
Load	Mass on column from pilot	Saturation or dropped transitions
SIS	Spike step aligned to claim	Relative peaks read as concentration
QC	Pools, blanks, and bracket pattern	Undetected batch drift
Contrast	Frozen before peak review	Post hoc arm relabeling
Deliverable	Table, reaction list, method notes	Report rebuilt after acquisition

Limits follow the same table. SRM does not screen unknowns. Adding reactions without peak-width review can break sampling. High sensitivity language does not replace matrix-matched selection of ion pairs. Food, environmental, or small-molecule residue SRM uses different libraries and claim units than peptide proteomics.

How to Choose Selected Reaction Monitoring Versus Other Routes

Use list status, reaction pilot outcome, claim unit, and reagent constraints together.

Project need	Route that often fits	Recheck before committing
Closed peptides, stable selected reactions	SRM or MRM	Discovery LFQ as the targeted table
Reaction ratios unstable after CE lock	PRM subset or hybrid panel	Keep failing reactions on the SRM list
Open proteome relative profiling	Discovery LFQ or DIA first	SRM on unnamed proteins
Amount on named peptides	SRM or PRM with SIS and curve	Relative peaks as concentration
No antibody available, peptide surrogate exists	SRM after uniqueness pilots	Assume SRM equals ELISA epitope
Antibody assay already validated	Keep ELISA or hybrid design	Force SRM without peptide evidence
Food, environmental, or residue question	Separate small-molecule SRM assay	Peptide protein-inference rules

Figure 2. Choose SRM when selected reactions are stable in matrix; use PRM, discovery, or antibody routes when list status, interference, or epitope needs differ.

Teams with selected-reaction drafts, contrast maps, and matrix notes can review MtoZ Biolabs SRM-MRM Quantitative Proteomics Services when those fields are declared in the project record.

Frequently Asked Questions

1. Is selected reaction monitoring the same as MRM?

In most targeted proteomics briefs, yes. Both name scheduled precursor-product monitoring. MRM usually stresses a multi-transition schedule. The record should lock one name and one reaction list.

2. Does SRM replace ELISA for every protein target?

No. SRM avoids antibody generation when proteotypic peptides work. ELISA measures antibody-defined epitopes. Feasibility depends on peptide uniqueness, matrix pilots, and the declared claim, not on SRM alone.

3. Can SRM quantify many proteins in one run?

Yes within cycle-time limits. Each added reaction consumes dwell. Throughput rises only while chromatographic peaks remain adequately sampled.

4. Must every SRM project use SIS peptides?

No. Relative contrasts can run light-only when that claim is declared. SIS and a curve become necessary when amount units are required.

5. When should projects move from SRM to PRM?

When matrix-matched pilots still show unstable transition ratios after reaction filtering and collision-energy work, a PRM subset can be scoped.

MtoZ Biolabs can discuss selected reaction monitoring scoping when reaction list, pretreatment parity, and contrast design are documented.

If further evaluation of SRM versus PRM, SIS calibration, or antibody-to-SRM handoff is needed, project details can be submitted for a feasibility review.

Reference

1. V. Lange, P. Picotti, B. Domon, R. Aebersold (2008). Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol., 4, 222. https://doi.org/10.1038/msb.2008.61
2. A.C. Peterson, J.D. Russell, A.A. Klammer, P.F. Doubleday, H. Liu, J.N. Anderson, M.J. MacCoss (2012). Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol. Cell. Proteomics, 11, 1475-1488. https://doi.org/10.1074/mcp.O112.020271
3. S.A. Gerber, J. Rush, O. Stemman, M.W. Kirschner, S.P. Gygi (2003). Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc. Natl. Acad. Sci. U.S.A., 100, 6940-6945. https://doi.org/10.1073/pnas.0832254100
4. M. Bantscheff, S. Lemeer, H.U. Haab, B. Kuster (2012). Quantitative mass spectrometry in proteomics: a critical review. Anal. Bioanal. Chem., 404, 939-965. https://doi.org/10.1007/s00216-012-5892-4
5. S. Gallien, E. Duriez, A. Crone, M. Kellmann, T. Moehring, T. Domon (2012). Targeted proteomic quantification on quadrupole-orbitrap mass spectrometers. Mol. Cell. Proteomics, 11, 1709-1723. https://doi.org/10.1074/mcp.O112.019232